Cecilia Brown

Articles by Cecilia Brown

Cecilia BrownTransplantation & Cellular Therapy | December 2, 2022
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Read More
Cecilia BrownMyeloma | December 2, 2022
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
Cecilia BrownMyeloma | December 2, 2022
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
Cecilia BrownAcute Myeloid Leukemia | December 1, 2022
Nicholas Short, MD, on his hopes for the new year in blood cancer. 
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Leah SherwoodChronic Myeloid Leukemia | November 23, 2022
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.
Cecilia BrownPrint | November 23, 2022
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Cecilia BrownPrint | November 23, 2022
Baseline genetic characteristics are the primary determinants of allogeneic HSCT outcomes in older adults with AML.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.